The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci
Abstract
Objectives To describe the efficacy and safety of quinupristin-dalfopristin (Q-D) as rescue therapy in critically ill patients with severe infections caused by methicillin-resistant staphylococci unresponsive to vancomycin treatment. Design Observational study in the context of the compassionate use programme for Q-D. Methods Twelve mechanically ventilated patients suffering from severe staphylococcal infections, pretreated unsuccessfully with vancomycin despite in vitro sensitivity, were included. Patients received, intravenously, Q-D 7.5 mg/kg body weight 3 times daily. The duration of Q-D therapy averaged 11.8 days (range: 1-26 days). The outcome variables were clinical efficacy and bacteriological eradication. Results Methicillin-resistant Staphylococcus aureus (MRSA) and Staphylococcus epidermidis (MRSE) were isolated in three patients each, and both bacteria were isolated from six patients. Eradication of pathogen(s) was achieved in 7 of 12 patients (66%). Five patients (42%) died due to severe co-morbidity. Adverse events related to Q-D were not observed and neither renal nor liver function was adversely affected. Conclusions Quinupristin-dalfopristin appears to be an efficient and safe antimicrobial drug for the rescue treatment of staphylococcal infections in critically ill patients. It may be considered as a treatment option in cases of vancomycin treatment failure.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Quinupristin-dalfopristin 177 and telavancin 178 have been used successfully as salvage therapy in selected patients with MRSA IE who clinically failed vancomycin therapy.”
Citations
Cites
Bone, R. C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-6-457 · Cited by 1,368
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333 · cited 1×
“though some cases of glycopeptide intermediate isolates of Staphylococcus aureus (GISA) associated with vancomycin treatment failure have been reported [1, 2, 3], the”
Emergence of Vancomycin Resistance in Staphylococcus aureus
Smith, T. L., Pearson, M. L., Wilcox, K. R., Cruz, C., Lancaster, M. V., Robinson-Dunn, B., Tenover, F. C., Zervos, M. J., Band, J. D., White, E., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902183400701 · Cited by 1,088 · cited 1×
“though some cases of glycopeptide intermediate isolates of Staphylococcus aureus (GISA) associated with vancomycin treatment failure have been reported [1, 2, 3], the”
Sepsis: A New Hypothesis for Pathogenesis of the Disease Process
Bone, R. C., Grodzin, C. J., & Balk, R. A. (1997) · Chest · doi:10.1378/chest.112.1.235 · Cited by 1,021 · cited 1×
“First, all patients were critically ill and, presumably, immunocompromised due to therapeutic immunosuppression or multiple organ dysfunction [16].”
Infectious Complications of Indwelling Vascular Catheters
Raad, I. I., & Bodey, G. P. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/15.2.197 · Cited by 446 · cited 1×
“Staphylococcal septicaemia represents difficult-to-treat and often lethal infections in patients with vascular catheters and prosthetic valves [7].”
Penetration of vancomycin into human lung tissue
Cruciani, M., Gatti, G., Lazzarini, L., Furlan, G., Broccali, G., Malena, M., Franchini, C., & Concia, E. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.5.865 · Cited by 264 · cited 1×
“The majority of treatment failures may rather be related to vancomycin’s pharmacokinetic and pharmacodynamic properties [ 4 , 5] (e.g.”
FAGON, J.-Y., PATRICK, H., HAAS, D. W., TORRES, A., GIBERT, C., CHEADLE, W. G., FALCONE, R. E., ANHOLM, J. D., PAGANIN, F., FABIAN, T. C., et al. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.3.9904115 · Cited by 214 · cited 1×
“and tissue infections [9, 10], data for ICU patients are A.”
Nichols, R. L., Graham, D. R., Barriere, S. L., Rodgers, A., Wilson, S. E., Zervos, M., Dunn, D. L., & Kreter, B. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.263 · Cited by 177 · cited 1×
“and tissue infections [9, 10], data for ICU patients are A.”
Drew, R. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.775 · Cited by 165 · cited 1×
“While some data derived from the world-wide Q-D compassionate use programme have been published [11], most patients included were not treated in an ICU.”
Increasing Bacteremia Due to Coagulase-Negative Staphylococci: Fiction or Reality?
Thylefors, J., Harbarth, S., & Pittet, D. (1998) · Infection Control and Hospital Epidemiology · doi:10.1086/647878 · Cited by 108
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
“Quinupristin-dalfopristin has been used successfully as salvage therapy in patients with vancomycin treatment failure [65], although response rates were lower for patients with endocarditis and bacteremia of unknown source [64].”
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Moreillon, P., & Que, Y.-A. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15266-x · Cited by 861
Sakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
“Nevertheless, vancomycin treatment failures are not uncommon with MRSA infections despite the organism being fully susceptible (vancomycin MIC 2 g/ml) by standard methods of testing and criteria (6, 7, 8, 10, 17, 18, 26).”
MethodHassoun, A., Linden, P. K., & Friedman, B. (2017) · Critical Care · doi:10.1186/s13054-017-1801-3 · Cited by 604
“epidermis infections that did not respond to vancomycin, five of seven MRSA bacteremic patients showed eradication of the bacteria [80].”
Background
Metadata
- Authors
- Sander, A., Beiderlinden, M., Schmid, E., & Peters, J.
- Affiliations
- Essen University Hospital (DE)
- Corresponding author
- Sander, A.
- ORCID
- Beiderlinden, M.
- Venue
- Intensive Care Medicine
- Published
- 2002-08
- Volume
- 28
- Issue
- 8
- Pages
- 1157-1160
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W2010194702
- Semantic Scholar
- 0d7a10244931aba11657b5a0fe02b414cc977f44
- Cited by
- 29
- References
- 19
- Citations by year
- 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 1 · 2015: 2 · 2013: 1
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Intensive Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- quinupristin/dalfopristin, methicillin-resistant Staphylococcus aureus, methicillin-resistant Staphylococcus epidermidis, salvage therapy, critically ill patients, mechanically ventilated patients, bacteriological eradication, drug safety, compassionate use
- MeSH terms
- Adult, Aged, Anti-Bacterial Agents, Critical Care, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Staphylococcal Infections, Staphylococcus aureus, Staphylococcus epidermidis, Virginiamycin, Methicillin Resistance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. https://app.cochat.ai/papers/10.1007/s00134-002-1358-7
- The paper
- Sander, A., Beiderlinden, M., Schmid, E., & Peters, J. (2002). Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Medicine. https://doi.org/10.1007/s00134-002-1358-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.